ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
트랜스티레틴 아밀로이드증 치료 시장 규모는 2025년 732만 달러에서 2034년에는 1,560만 달러에 달할 것으로 예측되고 있으며, 2026-2034년에 CAGR 8.77%로 성장할 전망입니다.
트랜스실레틴아밀로이드증 치료제 시장은 희귀질환에 대한 인식과 진단율 향상에 따라 큰 폭의 성장이 예상됩니다. 트랜스실레틴아밀로이드증(ATTR)은 다양한 조직에 아밀로이드 단백질이 축적되어 장기 기능 장애를 유발하는 진행성 질환입니다. 특히 고령화 사회에서 ATTR의 유병률이 증가하고 있는 것이 효과적인 치료법에 대한 수요를 견인하고 있습니다. 의료 서비스 프로바이더가 환자의 치료 성과와 삶의 질 향상을 목표로 하는 가운데, ATTR 치료 시장은 확대될 것으로 예측됩니다.
기술 혁신은 트랜스티레틴 아밀로이드증 치료 시장 전망를 형성하는 데 중요한 역할을 하고 있습니다. 저분자 치료 및 유전자 침묵 기술을 포함한 신약 개발 분야의 혁신으로 아밀로이드 침착 억제 및 증상 관리를 위한 치료의 효과가 향상되고 있습니다. 또한 진단 툴의 발전으로 질병의 조기 발견과 보다 정확한 경과 관찰이 가능해져 적시에 개입할 수 있는 기반이 마련되고 있습니다. 제약사들이 연구개발에 대한 투자를 지속하고 있는 가운데, 트랜스실레틴아밀로이드증 치료제 시장은 새로운 치료법의 도입 확대와 환자 관리 전략의 개선이 이루어질 것으로 예측됩니다.
또한 환자 중심의 치료와 지원에 대한 관심이 높아지면서 트랜스티레틴 아밀로이드증 치료제 시장의 성장 궤도에 영향을 미치고 있습니다. 환자와 가족들이 질병과 치료 옵션에 대해 더 많은 정보를 얻게 됨에 따라 의료적 필요와 정신적 필요를 모두 충족시킬 수 있는 종합적인 케어 플랜에 대한 수요가 증가하고 있습니다. 이러한 추세는 의료진, 환자 지원 단체, 연구자 간의 협력을 촉진하고, 환자가 치료 과정에서 힘을 얻을 수 있도록 돕는 교육 자료와 지원 네트워크의 개발을 촉진하고 있습니다. 시장이 계속 진화하는 가운데, 기술 통합, 환자 참여, 종합적인 치료 접근법이 성공의 열쇠가 될 것입니다.
목차
제1장 서론
제2장 개요
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 약제 유형별
제5장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 질환 유형별
제6장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 최종사용자별
제7장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 유통 채널별
제8장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSA
영문 목차
영문목차
The Transthyretin Amyloidosis Treatment Market size is expected to reach USD 15.60 Million in 2034 from USD 7.32 Million (2025) growing at a CAGR of 8.77% during 2026-2034.
The Transthyretin Amyloidosis Treatment Market is poised for significant growth as awareness and diagnosis of this rare disease increase. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the accumulation of amyloid proteins in various tissues, leading to organ dysfunction. The rising prevalence of ATTR, particularly among aging populations, is driving the demand for effective treatment options. As healthcare providers seek to improve patient outcomes and quality of life, the market for ATTR treatments is expected to flourish.
Technological advancements are playing a crucial role in shaping the future of the transthyretin amyloidosis treatment market. Innovations in drug development, including small molecule therapies and gene silencing techniques, are enhancing the efficacy of treatments aimed at reducing amyloid deposits and managing symptoms. Additionally, advancements in diagnostic tools are enabling earlier detection and more accurate monitoring of the disease, which is critical for timely intervention. As pharmaceutical companies continue to invest in research and development, the transthyretin amyloidosis treatment market is likely to see increased adoption of novel therapies and improved patient management strategies.
Moreover, the growing emphasis on patient-centered care and support is influencing the transthyretin amyloidosis treatment market's growth trajectory. As patients and their families become more informed about the disease and available treatment options, there is a rising demand for comprehensive care plans that address both medical and emotional needs. This trend is driving collaboration between healthcare providers, patient advocacy groups, and researchers to develop educational resources and support networks that empower patients in their treatment journey. As the market continues to evolve, the integration of technology, patient engagement, and holistic care approaches will be key drivers of success.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Drug Type
Tafamidis
Patisiran
Inotersen
Others
By Diseases Type
Hereditary Transthyretin Amyloidosis
Wild Transthyretin Amyloidosis
By End User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
COMPANIES PROFILED
Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals, Bellus Health Inc, Alnylam Pharmaceuticals Inc, Eidos Therapeutics Inc, Som Biotech, Abbvie Inc, Bausch Health Companies Inc, Bristol Myers Squibb Company GSK Plc, Merck KGaA, Sanofi
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1 Information Analysis
1.3.2 Market Formulation & Data Visualization
1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
3.4.1 Standards & Compliance
3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
3.5.1 Market Drivers
3.5.2 Market Restraints
3.5.3 Market Opportunities
3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN and Units)
4.1. Market Analysis, Insights and Forecast Drug Type
4.2. Tafamidis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
4.3. Patisiran Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
4.4. Inotersen Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
Chapter 5. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DISEASES TYPE 2022-2034 (USD MN and Units)
5.1. Market Analysis, Insights and Forecast Diseases Type
5.2. Hereditary Transthyretin Amyloidosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
5.3. Wild Transthyretin Amyloidosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
Chapter 6. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY END USER 2022-2034 (USD MN and Units)
6.1. Market Analysis, Insights and Forecast End User
6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
6.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
Chapter 7. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Units)
7.1. Market Analysis, Insights and Forecast Distribution Channel
7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
7.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
7.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
Chapter 8. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN and Units)
8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
8.2.1 By Drug Type
8.2.2 By Diseases Type
8.2.3 By End User
8.2.4 By Distribution Channel
8.2.5 United States
8.2.6 Canada
8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
8.3.1 By Drug Type
8.3.2 By Diseases Type
8.3.3 By End User
8.3.4 By Distribution Channel
8.3.5 United Kingdom
8.3.6 France
8.3.7 Germany
8.3.8 Italy
8.3.9 Russia
8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
8.4.1 By Drug Type
8.4.2 By Diseases Type
8.4.3 By End User
8.4.4 By Distribution Channel
8.4.5 India
8.4.6 Japan
8.4.7 South Korea
8.4.8 Australia
8.4.9 South East Asia
8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
8.5.1 By Drug Type
8.5.2 By Diseases Type
8.5.3 By End User
8.5.4 By Distribution Channel
8.5.5 Brazil
8.5.6 Argentina
8.5.7 Peru
8.5.8 Chile
8.5.9 South East Asia
8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
8.6.1 By Drug Type
8.6.2 By Diseases Type
8.6.3 By End User
8.6.4 By Distribution Channel
8.6.5 Saudi Arabia
8.6.6 UAE
8.6.7 Israel
8.6.8 South Africa
8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY
